Abstract 31P
Background
Pancreatic cancer is the fourth most dominant disease leading the high mortality with a survival rate of 10%. Conventional therapeutics cause adverse effects as well as reoccurrence of pancreatic malignancy. Therefore, combination therapeutics including chemotherapy, photothermal, photodynamic, and immunotherapeutics has received great attention. The nanotechnological approaches are applied to develop the multifunctional nanocarrier to efficiently target the cancer cells without causing noticeable side effects. Therefore, herein we developed the multi-stimuli (pH, photothermal, and cancer cell receptor) responsive drug delivery system (DDS) for synergetic photothermal ablation of pancreatic cancer cells.
Methods
We synthesized the Au/Pd nanoparticles and conjugated them with 5-Fu using the CTAB. The 5fu-Au/Pd were loaded in CS through TPP ionic gelation. Then, apt was functionalized with 5fu-Au/Pd CS NPs by NHS and EDS covalent bonding method. The DDS (Apt-5fu-Au/Pd-CSNPs) were characterized for morphology, size, drug loading, entrapment, stimuli-responsive drug release, and photothermal conversion efficiency. Further, anticancer activity was evaluated in various molecular level cytotoxicity assays and animal tumor model experiments.
Results
DDS exhibited high drug loading and entrapment efficiency, and its size were exhibited <200 nm with a PDI of 0.23. The higher release of 5-Fu and Au/Pd were observed at the pH 5.4. This DDS exhibited the photothermal conversion efficiency of 28 %. The Apt-5fu-Au/Pd-CSNPs result in higher anticancer activity evidenced by the in-vitro cytotoxicity and animal experiments. The in vitro studies revealed that the treatment of Apt-5fu-Au/Pd-CSNPs triggers the cytotoxicity in the PANC-1 cells by regulating the MMP, ROS, apoptotic, and pro-apoptotic related proteins. The in-vivo studies reveal that the treatment of these DDS inhibited tumor proliferation and increase the mice's survival rate. And histopathological H & E staining studies confirmed the non-toxicity.
Conclusions
The present work delivered the novel nano DDS (Apt-5fu-Au/Pd-CSNPs) as an alternative to the conventional method of pancreatic cancer therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
6P - Deep learning radiomics supports perioperative treatment decisions and is associated with LncRNAs in breast cancer: A multicenter study
Presenter: Yunfang Yu
Session: Poster viewing 01
7P - Predicting lymph node metastasis and molecular subtype from pathology united with genomics in breast cancer with multitask deep learning
Presenter: Zehua Wang
Session: Poster viewing 01
8P - Dismantling the role of liquid biopsy in predicting outcome of patients with early-stage breast cancer following neoadjuvant therapy: A systematic review
Presenter: Jeremiah Wijaya
Session: Poster viewing 01
9P - Development and validation of a pathogenomics model to improve the risk stratification of breast cancer: A deep learning study
Presenter: lin ruichong
Session: Poster viewing 01
10P - Enriched gut microbiota increases anticancer drug efficacy in breast cancer cell lines: A promising in vitro approach
Presenter: Selvaraj Jayaraman
Session: Poster viewing 01
11P - Preservation of intercostobrachial nerve during axillary lymph node dissection in breast cancer patients positively impacts chronic pain, sensory changes, and quality of life: Should it be the standard?
Presenter: Ajai Sasidhar
Session: Poster viewing 01
12P - Non-clinical factors influencing patient’s choice of mastectomy over breast conservation among Indian women with breast cancer
Presenter: Nivedita Sharma
Session: Poster viewing 01
13P - Hypofractionated radiotherapy in post operative breast cancer patients: 3-year clinical experience in a newly established cancer center
Presenter: Shaila Sharmin
Session: Poster viewing 01
14P - The impact of the deep inspiration breath-hold (DIBH) technique in the heart and other organ-at-risk (OAR) dose sparing in the postoperative radiotherapy to the left early breast cancer
Presenter: Hui-Ling Yeh
Session: Poster viewing 01
15P - Delays in breast cancer treatment in a tertiary hospital
Presenter: Rogelio Velasco
Session: Poster viewing 01